Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Alector, Inc.NASDAQ: ALEC

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 110.59M shares rose 11.3% year over year, ahead of the +6.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.4% from the prior quarter. Over 3 fiscal years it compounded at +7.7% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +11.3% holds above the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
110.59M+7.4% QoQ
Last fiscal yearDec 2025
103M+6.6% YoY
LTMMar 2026
104.14M+6.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.3%——
1 year+6.6%——
3-year CAGR+7.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
103M USD
Year-over-year change
+6.6%
4-year CAGR
+6.4%

Weighted Avg Shares (Diluted) vs competitors

How ALEC compares with its peers on the latest reported figures

  • ALEC's LTM Mar 2026 weighted avg shares (diluted) of 104.14M shares is the 3rd highest of the 9 companies compared; the peer median is 49.36M shares.
  • Its year-over-year change of +6.5% is the 6th highest of 9, against a peer median of +12.0%.
  • Over three fiscal years its annual growth of +7.7% compares with a peer median of +29.2%.
ALEC Competitors Peer median
Weighted Avg Shares (Diluted) for ALEC and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+211.4%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
PEPGPepGen Inc.LTM Mar 202637.49M +15.0%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+3.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
VORVor Biopharma Inc.LTM Mar 20265.81M +40.8%+70.9%
Peer median (excluding ALEC) 49.36M+12.0%+29.2%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.